The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2025 | Improvements in the molecular classification of DLBCL
In this video, Margaret Shipp, MD, Dana-Farber Cancer Institute, Boston, MA, notes that the ability to molecularly classify subtypes of diffuse large B-cell lymphoma (DLBCL) has significantly improved over the past decade, particularly with advancements in polyclonal sequencing and the ability to sequence formalin-fixed paraffin-embedded samples. Dr Shipp highlights an emerging consensus in the field regarding the basis of genetic heterogeneity in DLBCL and emphasizes the need to develop strategies to prospectively capture this information in patients to inform targeted therapies and clinical trial design. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that our ability to classify at a molecular level subtypes of DLBCL has really improved, particularly over maybe the last five or six years with the advent of polyclonal sequencing and the advent of being able to comprehensively sequence tumors that would normally be challenging, and these are formalin-fixed paraffin-embedded samples, and we’ve overcome some of the technical challenges in terms of doing that...
I think that our ability to classify at a molecular level subtypes of DLBCL has really improved, particularly over maybe the last five or six years with the advent of polyclonal sequencing and the advent of being able to comprehensively sequence tumors that would normally be challenging, and these are formalin-fixed paraffin-embedded samples, and we’ve overcome some of the technical challenges in terms of doing that. And I think that there’s an emerging consensus in the field based on work that’s been done actually now by several different independent groups coming to a consensus on the basis of the genetic heterogeneity, DNA-based heterogeneity, in diffuse large B-cell lymphoma. And so the next challenge will be thinking about how you are able to prospectively capture that information on patients going forward so that then you could potentially develop clinical trials based on patients’ vulnerabilities that could be targeted based on their genetic category and also for thinking about how that might impact therapy in the regular clinic as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
